Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now. On February 15, at the Guggenheim ...
Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% ...
In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.
Syndax Pharmaceuticals Inc. reports fourth-quarter results after the market close Thursday, with investors focused on whether the biotech’s recently launched cancer therapies can sustain commercial ...
New research suggests childhood cancer survivors may experience accelerated biological aging from treatments, potentially ...
Objective: To explore the risk factors for perianal infections in patients with neutropenia and evaluate the effectiveness of different preventive measures. Methods: A r ...
XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for ...
Blackstone Life Sciences announced a research and development funding agreement to advance the clinical development of bleximenib, an investigational oral menin inhibitor, for acute myeloid leukemia ...
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and ...
Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a robust ...
Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc® to the U.S. Food and Drug Administration (FDA). Dasynoc® is the company's lead product candidate - an amorphou ...
According to MarketsandMarkets™, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results